A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy.

Trial Profile

A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Hydrochlorothiazide; Olmesartan medoxomil/amlodipine
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms BP CRUSH
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2010 Preliminary results were presented during the late breaker poster session of the American Society of Hypertension (ASH) annual meeting, according to a Daiichi Sankyo media release.
    • 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top